

REMARKS


As noted above, in response to the Restriction Requirement dated March 15, 2004, applicants have elected Group I, claims 1,3, 4, 8, 11-in-part (b) and 15, drawn to isolated polynucleotides, kits, and compositions comprising those polynucleotides, vectors, and transformed host cells, for examination at this time. Applicants have also elected species SEQ ID NO: 343, the polynucleotide sequence encoding a variant C/A isoform of the breast tumor antigen, B305D. In view of the election, Applicants have canceled claims 2, 5-7, 9-10, 12-14, and 16-17. Claims 1, 8, and 11 have been amended solely to remove reference to non-elected subject matter. It should be noted that the above amendments are made without prejudice to prosecution of any subject matter removed or modified by this amendment in a related divisional, continuation or continuation-in-part application.

Further in view of the above election, Applicants submit herewith a supplemental ADS amending the domestic priority information.

Consideration of the elected claims is now requested.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



Julie A. Urvater, Ph.D., Patent Agent
Registration No. 50,461

JAU:tt

Enclosure:

Postcard

Supplemental ADS

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031
474185_1.DOC